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Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a
preoperative prognostic indicator in advanced ovarian cancer
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Department of'Obstetrics and Gynaecology and 2Clinical Chemistry Helsinki University Central Hospital, Helsinki, Finland.
Summary We have evaluated the prognostic value of tumour-associated trypsin inhibitor (TATI) in stage III
or IV ovarian cancer. Tumour-associated trypsin inhibitor (TATI) and CA 125 were determined in serum
samples from 66 patients taken before primary surgery. TATI was elevated (> 22jug 1-) in 27 patients (41%).
These had a 5 year cumulative survival of 8%, whereas survival was 45% in 39 patients with normal
preoperative TATI values. By contrast, the preoperative CA 125 level did not predict survival. In multivariate
analysis which included age, stage, histological grade and preoperative TATI and CA 125 levels, patients with
elevated preoperative TATI levels had a 2.3-fold relative risk of death (95% confidence interval 1.23-4.20;
P = 0.002) compared with patients with normal preoperative levels. This result was comparable with the
predictive value of primary residual tumour size, since patients with residual tumour larger than 2 cm in
diameter had a 5.2-fold relative risk of death (95% confidence interval 2.55-10.68) compared with patients
with a smaller or no residual tumour. Thus, preoperative determination of serum TATI may have a place in
the pretreatment evaluation of patients with advanced ovarian cancer.
There is a great need for biochemical markers which could
reliably reveal the aggressiveness of ovarian tumours before
therapy. Such markers could aid clinicians in identifying
patients in whom it would be wise to abstain from extensive
cytoreductive surgery. CA 125 in serum is a sensitive marker
for diagnosis and follow-up of ovarian cancer (Bast et al.,
1983), but the preoperative CA 125 level does not predict
prognosis (Makar et al., 1992). However, rapid normalisation
of the CA 125 level after surgery correlates with a good
prognosis (Rosen et al., 1990). Patients with elevated serum
CA 125 values 3 months after surgery have a 3.1-fold risk of
dying of ovarian cancer compared with patients with normal
values (Sevelda et al., 1989). However, this information is
available only after therapy.
Another potentially useful marker for ovarian cancer,
tumour-associated trypsin inhibitor (TATI) (Stenman et al.,
1982), is most specific for mucinous tumours, being elevated
preoperatively in approximately half of the patients already
in stage I disease (Halila et al., 1988; Mogensen et al., 1990).
However, TATI is also elevated at advanced stages of other
types of ovarian cancer (Huhtala et al., 1983; Halila et al.,
1988; Mogensen et al., 1990). Thus, TATI could be a comple-
ment to CA 125 as a marker for the aggressiveness of
ovarian cancer. We have therefore studied the predictive
value of CA 125 and TATI in serum before surgery in
patients with stage III or IV ovarian cancer. We also studied
the values 3 months post-operatively.
Materials and methods
Sixty-six patients 15-86 (median 58) years of age with
advanced (stage III or IV) ovarian cancer and with elevated
preoperative CA 125 levels were studied with approval of the
local ethical committee. Only two patients had a mucinous
cancer (Table I). After surgery 61 patients received a mean of
eight courses (range 1-20) of chemotherapy with a combina-
tion of cisplatin (50 mg m-2), doxorubicin (40 mg mi-2) and
cyclophosphamide (500 mg mi-2). One patient received
chemotherapy with a combination of doxorubicin and cyclo-
phosphamide. Four patients did not receive any chemo-
therapy. Surgery and follow-up ranging from 33 to 69
months (median 52) were performed in the same hospital.
CA 125 and TATI were analysed in serum samples ob-
tained within 1 week before surgery in all patients and 3
months after surgery (i.e. after three courses of chemo-
therapy) in a subgroup of 25 patients. The CA 125 assay was
performed by an immunoradiometric assay according to the
manufacturer's instructions (Abbot Diagnostics). On the
basis of earlier reports (Bast et al., 1983; Halila et al., 1986)
values greater than 35 U ml-' were considered elevated.
TATI was measured by radioimmunoassay using reagents
from Orion Diagnostica as previously described, and levels
exceeding 22 jig 1- were considered elevated (Stenman et al.,
1982).
Statistical analysis was performed using BMDP programs
(Dixon, 1981). Survival curves were calculated with the
BMDP1L program and survival analysis with covariates
(Cox model) with the BMDP2L program. The Mantel-Cox
test was used for calculating statistical significance of survival
differences.
Results
Preoperatively, serum CA 125 levels ranged from 47 Uml'
to 188,000 U ml-' (mean 4,542 U ml-'). Twenty-seven (41%)
women had elevated preoperative TATI levels ranging from
22.4Lgl-' to 389 igl-l (mean 87.3gAgl-') and in 39 the
levels were normal ranging from S to 22 tgll (mean
12.5ftgl-'). The frequency of elevated TATI levels in rela-
tion to stage, histological type and grade, and size of residual
tumour is shown in Table I.
The magnitude of the preoperative CA 125 elevation did
not predict survival: high levels were actually associated with
a lower risk, but the difference was not significant (Table II).
In contrast, patients with high preoperative TATI levels had
significantly worse cumulative 5 year survival than did
patients with normal preoperative TATI levels (P = 0.002)
(Figure 1). In multivariate analysis comprising age, stage,
histological grade, primary residual tumour size and
preoperative TATI and CA 125 levels the patients with
elevated preoperative TATI levels had a 2.3-fold relative risk
of death (95% confidence interval 1.23-4.20; P = 0.002)
compared to those with normal levels (Table II).
In a subgroup of 25 women the CA 125 and TATI levels
were determined 3 months after primary surgery. Three
months after operation and three courses ofchemotherapy 11
patients had an elevated value of either marker. Six had
elevated CA 125 levels (mean 400 U ml-', range
38-1,685 U ml-'), and six (three with initial high TATI) had
high TATI levels ranging from 25 to 70 tg 1' (mean
Correspondence: P. Venesmaa, Department of Obstetrics & Gynae-
cology, University Central Hospital, Haartmaninkatu 2, SF-00290
Helsinki, Finland.
Received 6 May 1993: and in revised form 14 March 1994.
Br. J. Cancer (1994), 70, 1188-1190 '." Macmillan Press Ltd., 1994PREOPERATIVE TATI IN OVARIAN CANCER 1189
Table I Clinical and histopathological characteristics of the 66 patients with
advanced ovarian cancer in relation to the preoperative serum TATI levels
Preoperative TATI level
Normal Elevated
n n(%) n(%)
Stage
III 58 34 (59) 24 (41)
IV 8 5 (63) 3 (38)
Histological type
Serous 38 26 (68) 12 (32)
Mucinous 2 1 (50) 1 (50)
Endometrioid 1 0 (0) 1 (100)
Clear cell 4 2 (50) 2 (50)
Undifferentiated 17 7 (41) 10 (59)
Stromal cell 4 3 (75) 1 (25)
Histological grade
1 9 6 (67) 3(33)
2 14 8 (57) 6 (43)
3 38 21 (55) 17 (45)
Not defined 5 4 (80) 1 (20)
Size of residual tumour at primary operation
No macroscopic tumour 15 10 (67) 5 (33)
<2cm 16 11(69) 5(31)
>2cm 35 18 (51) 17 (49)
Total 66 39 (59) 27 (41)
Table II Multivariate analysis of 66 patients with advanced ovarian
cancer: relative risk of death according to age, stage, histological
grade, primary residual tumour size, and preoperative level of
tumour-associated trypsin inhibitor (TATI) and CA 125
RR (95% CI) P-value
Age (years)
(50 1
> 51 0.62 (0.24-1.58) 0.356
Stage
III I
IV 1.25 (0.54-2.89) 0.158
Histological grade
1-2 1
3 1.53 (0.69-3.41) 0.016
Primary residual tumour size
<2cm I
>2 cm 5.22 (2.55-10.68) <0.001
Preoperative TATI
<22jig I-' (normal) 1
>22jig 1-' (elevated) 2.27 (1.23-4.20) 0.002
CA 125
<200Uml'm1
200-1,000 U ml' 0.77 (0.27-2.18)
1,000 U ml' 0.63 (0.36-1.09) 0.448
47fgg-'). Patients with normal CA 125 and TATI levels 3
months after surgery (n = 14) had a cumulative 5 year sur-
vival of 52% as compared with 9% in the patients with
elevated CA 125 or TATI levels 3 months post-operatively.
All patients with 3 months' TATI elevation died within 36
months after surgery, and they had a 6.1-fold (95% CI
2.0-19.0) relative risk of death. Those with TATI and/or CA
125 elevation had a 2.5-fold (95% CI 1.5-4.2) risk of death,
and those with only CA 125 elevated had a 2.8-fold risk of
death (95% CI 0.9-8.3) compared with patients with normal
marker levels.
Discussion
The majority of patients with ovarian cancer are diagnosed
at stage III and IV when the disease often cannot be con-
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Figure 1 Cumulative survival curves (based on Mantel-Cox
analysis) of 66 patients with advanced ovarian cancer in relation
to preoperative TATI levels.
trolled by surgery or cytotoxic regimens, thus the 5 year
survival is only 23% in stage III and 8% in stage IV patients
(Pettersson, 1991). In these patients a reliable biochemical
marker predicting the outcome prior to primary surgery
would be valuable for making treatment decisions. In concert
with earlier studies (van der Burg et al., 1988; Sevelda et al.,
1989; Mogensen, 1992) we found that the preoperative level
of CA 125 did not predict outcome. By contrast, an elevated
preoperative TATI level was strongly correlated with a poor
prognosis.
The mechanism causing elevation of TATI in non-mucinous
ovarian cancer is not clear, but it has been postulated that a
reaction against tumour invasion may trigger the expression
of TATI (Stenman et al., 1991). The target protease of TATI
is tumour-associated trypsin (Koivunen et al., 1989), which
can participate in the protease cascade associated with in-
vasive tumours (Koivunen et al., 1991). TATI and tumour-X1190 P. VENESMAA et al.
associated trypsin are usually expressed simultaneously. Thus
a high preoperative TATI level may reflect the proteolytic
activity and invasiveness of the tumour (Stenman et al.,
1991). This would explain the correlation between elevated
TATI levels and a poor prognosis.
Earlier studies have shown that the CA 125 level 3 months
after surgery correlates strongly with survival (Lavin et al.,
1987; Sevelda et al., 1989; Mogensen, 1992). Our study sug-
gests that in patients with advanced disease the TATI level
before therapy has a predictive value similar to that of CA
125 3 months after therapy. In addition, all patients with
high TATI levels 3 months post-operatively died within 36
months. The prognosis was best if both CA 125 and TATI
were normal 3 months post-operatively.
Our results suggest that determination of TATI before
therapy and the combined determination of TATI and CA
125 3 months after surgery can be used as an aid for making
treatment decisions in patients with advanced ovarian
cancer.
This study is supported by grants from the Emil Aaltonen Found-
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